Search research articles
Contact Us
Filters
Showing results (31-40 of 36) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 36 results.
Oncoimmunology
|
December 14, 2020
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Neeta Somaiah, Sant P Chawla, Matthew S Block, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 18, 2022
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
Joseph W Kim, Rana R McKay, Marc R Radke, et al.
BJU International
|
September 24, 2020
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer
Ravi A Madan, Fatima H Karzai, Munjid Al Harthy, et al.
BMC Public Health
|
September 17, 2024
Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing
Amy E Leader, Timothy R Rebbeck, William K Oh, et al.
The New England Journal of Medicine
|
September 16, 2024
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
Andrea B Apolo, Karla V Ballman, Guru Sonpavde, et al.
Journal of the National Cancer Institute
|
August 11, 2023
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors
Talal El Zarif, Amin H Nassar, Gregory R Pond, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 36) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 36 results.
Oncoimmunology
|
December 14, 2020
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Neeta Somaiah, Sant P Chawla, Matthew S Block, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 18, 2022
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
Joseph W Kim, Rana R McKay, Marc R Radke, et al.
BJU International
|
September 24, 2020
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer
Ravi A Madan, Fatima H Karzai, Munjid Al Harthy, et al.
BMC Public Health
|
September 17, 2024
Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing
Amy E Leader, Timothy R Rebbeck, William K Oh, et al.
The New England Journal of Medicine
|
September 16, 2024
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
Andrea B Apolo, Karla V Ballman, Guru Sonpavde, et al.
Journal of the National Cancer Institute
|
August 11, 2023
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors
Talal El Zarif, Amin H Nassar, Gregory R Pond, et al.
Page
of 4